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OBJECTIVES We sought to determine the effect of aspirin on the venodilator effect of furosemide in
patients with chronic heart failure (CHF)
BACKGROUND Furosemide has an acute venodilator effect preceding its diuretic action, which is blocked by
nonsteroidal anti-inflammatory drugs. The ability of therapeutic doses of aspirin to block this
effect of furosemide in patients with CHF has not been studied. For comparison, the
venodilator response to nitroglycerin (NTG) was also studied.
METHODS Eleven patients with CHF were randomized to receive placebo, aspirin at 75 mg/day or
aspirin at 300 mg/day for 14 days in a double-blind, crossover study. The effect of these
pretreatments on the change in forearm venous capacitance (FVC) after 20 mg of intravenous
furosemide was measured over 20 min by using venous occlusion plethysmography. In a
second study, the effect of 400 mg of sublingual NTG on FVC was documented in 11 similar
patients (nine participated in the first study).
RESULTS Mean arterial pressure, heart rate and forearm blood flow did not change in response to
furosemide. After placebo pretreatment, furosemide caused an increase in FVC of 2.2% (95%
confidence interval [CI] 20.9% to 5.2%; mean response over 20 min). By comparison, FVC
fell by 21.1% (95% CI 24.2% to 1.9%) after pretreatment with aspirin at 75 mg/day, and by
23.7% (95% CI 26.8% to 20.7%) after aspirin at 300 mg/day (p 5 0.020). In the second
study, NTG increased FVC by 2.1% (95% CI 21.6% to 5.8%) (p 5 0.95 vs. furosemide).
CONCLUSIONS In patients with CHF, venodilation occurs within minutes of the administration of
intravenous dose of furosemide. Our observation that aspirin inhibits this effect further
questions the use of aspirin in patients with CHF. (J Am Coll Cardiol 2001;37:1234–8) ©
2001 by the American College of Cardiology
Intravenous furosemide is commonly administered to pa-
tients with acute heart failure to relieve pulmonary conges-
tion through diuresis. However, it has been observed for
some time that symptomatic relief occurs in these patients
before the onset of diuresis (1–3). This effect is believed to
result from an independent venodilator action, which pre-
cedes the diuretic effect of furosemide (4). This venodilator
response to furosemide is inhibited by the cyclooxygenase
inhibitor indomethacin (5,6). It is believed, therefore, that
venodilation is brought about through the release of local
prostaglandins (5,6).
Our hypothesis was that aspirin might also inhibit the
acute venodilator response to furosemide in patients with
chronic heart failure (CHF). The present study was de-
signed to determine whether clinically relevant doses of
aspirin (75 mg/day and 300 mg/day) affected this response
to furosemide in patients who continued with all other
prescribed heart failure medications, as normal. We also
studied the immediate venodilator response to sublingual
nitroglycerin (NTG) to compare its effect with that of
furosemide.
METHODS
Subjects. The study was performed with the approval of
the Local Ethics Committee of the West Glasgow Univer-
sity Hospital NHS Trust. All patients gave written, in-
formed consent. To study the effects of aspirin on the
response to furosemide, 11 patients (10 men and 1 woman;
mean [6SD] age 70 6 7 years) with chronic heart failure
(CHF) were studied. Patients had New York Heart Asso-
ciation class II or III CHF caused by left ventricular systolic
dysfunction, confirmed by a left ventricular ejection fraction
,40% on echocardiography. All patients were clinically
stable and received a constant dose of an angiotensin-
converting enzyme inhibitor. All medications, apart from
aspirin, remained unchanged throughout the study period.
To study the response to sublingual NTG, we studied 11
patients (10 men and 1 woman; mean [6SD] age 70 6 7
years) similar to those who completed the furosemide
protocols. Nine of these patients had participated in the
furosemide arm of the study; the method of diagnosis and
the severity of heart failure were the same as described
previously.
Patients were not studied if they had a history of a recent
myocardial infarction or cerebrovascular event, or a history
of a clinically important hepatic, gastrointestinal, hemato-
logic, endocrine, renal, pulmonary or neurologic disorder.
Patients with uncontrolled or insulin-dependent diabetes
mellitus or uncontrolled hypertension were also excluded.
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Warfarin therapy or known intolerance to nonsteroidal
anti-inflammatory drugs, acetaminophen (paracetamol) or
nitrates was used as the final exclusion criteria.
Study design. Each patient was studied on three separate
occasions in a randomized, double-blind, crossover proto-
col. Prescribed aspirin therapy was suspended for all pa-
tients, who were randomly assigned to 14 days of 75 mg
aspirin, 300 mg aspirin or 120 mg acetaminophen (as a
nonvasoactive placebo), taken once daily. Acetaminophen
was chosen as the placebo for this study to help ensure that
the study was done in blinded manner. The preparation of
this dose of acetaminophen was soluble, as were the two
doses of aspirin used. Acetaminophen at doses 25 times the
dose used in the present study does not alter the excretion of
the metabolites of prostaglandins, suggesting that it does
not inhibit prostaglandin production (7). At the end of each
treatment period, patients were studied using forearm ve-
nous occlusion plethysmography. During each 14-day pe-
riod, patients abstained from all other aspirin, aspirin-
containing or aspirin-like medications. On the day of the
plethysmographic study, patients attended the vascular lab-
oratory at least 5 h after their last light meal, having
abstained from alcohol, tobacco and caffeine for 24 h.
Patients were instructed to withhold their diuretic therapy
on the day of the study, but to take all other medication as
normal, including the therapy to which they were random-
ized at that time (i.e., aspirin 75 mg, aspirin 300 mg or
placebo [acetaminophen]).
The response to NTG was measured in patients whether
or not they were taking aspirin, as prescribed by their
physician. Patients were asked to attend one venous occlu-
sion plethysmographic study, having taken all medications
for that day, except for nitrate therapy, as normal. When the
patients’ therapy included nitrates, they were asked to
withhold the last dose that was scheduled before attending
the study.
Venous occlusion plethysmography protocol. Studies
were performed in a quiet laboratory, as previously de-
scribed, with the temperature controlled at 25°C (8–10).
Patients lay supine on a bed, and a 20-gauge intravenous
cannula (Biovalve, Vygon U.K. Ltd., Cirencester, United
Kingdom) was inserted into a vein in the left or right
forearm and then flushed with 5 ml of physiologic saline
solution (0.9% wt/wt NaCl, Steripak Ltd., Runcorn, United
Kingdom). In each patient, the forearm that was used to
place the cannula on the first study day was used on
subsequent study days.
Forearm blood flow and forearm venous capacitance
(FVC) were measured by venous occlusion plethysmogra-
phy using mercury-in-Silastic strain gauges (D.E. Hokan-
son Inc., Bellevue, Washington) placed around the forearm
at the point of greatest circumference (11). Blood flow was
measured from the rate of change in forearm circumference
after exclusion of the hand’s circulation by wrist cuffs
inflated to 220 mm Hg and inflation of upper-arm cuffs to
45 mm Hg for 12 s of every 16 s for 2 min, 30 s (8–10).
Venous capacitance was determined by the equilibration
technique at a venous occlusion pressure of 45 mm Hg for
2 min, 30 s. The cuffs were inflated using rapid cuff inflators
(Model E-20, D.E. Hokanson Inc.) (8–10).
Baseline recordings of forearm blood flow and forearm
venous capacitance (FVC) in both arms were made every
5 min for 20 min. At the end of 20 min, a 20-mg bolus of
furosemide (Antigen Pharmaceuticals, Roscrea, Ireland)
was administered over the course of 30 s through the
intravenous cannula placed in the forearm. The cannula was
then flushed with another 5 ml of physiologic saline
solution. Further measurements of forearm blood flow and
FVC were made at 5-min intervals for 20 min after the
administration of furosemide.
Measurement of the effects of NTG was conducted in
identical circumstances, except that instead of intravenous
furosemide, one dose of 400 mg NTG (Lipha Pharmaceu-
ticals Ltd., West Drayton, United Kingdom) was adminis-
tered sublingually.
Blood pressure and heart rate were measured at the same
intervals as venous capacitance using an automatic blood
pressure monitor (Dinamap Plus 8700; Johnson & Johnson,
Newport, United Kingdom), with a lower limb cuff wrapped
around the leg.
Voltage output from the plethysmographs (Model EC-4,
D.E. Hokanson Inc.) was transferred through MacLab/8E
(ADInstruments, Hastings, United Kingdom) to a Macin-
tosh personal computer (PowerMac, Apple Computers Inc.,
Cupertino, California) for analysis using Chart (version
3.2.8, ADInstruments) and Excel (version 4 for Macintosh,
Microsoft Corp., Seattle, Washington).
Data analysis. All hemodynamic data were analyzed with-
out knowledge of the treatment allocation. The baseline for
each period was taken as the last point before furosemide
administration. The study design has repeated measure-
ments over time (percent change over baseline FVC at 5, 10,
15 and 20 min) at each of three periods. The data were
analyzed using a covariance pattern, mixed model, as pre-
viously described (12,13), with treatments, time, period and
treatment crossed with time as the fixed effects, assuming a
compound symmetry covariance pattern for the measure-
ments over time. For the parallel groups’ comparison of
NTG versus furosemide with placebo, a covariance pattern,
mixed model, assuming compound symmetry over the four
post-dose time points, was fitted (14). For both the cross-
over and parallel groups’ models, when no treatment by time
interaction was found, the main effects model was used. The
p values and 95% confidence intervals (CIs) for the three
Abbreviations and Acronyms
CHF 5 chronic heart failure
CI 5 confidence interval
FVC 5 forearm venous capacitance
NTG 5 nitroglycerin
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adjusted pairwise comparisons of treatment mean values
(low vs. high dose aspirin and low and high dose aspirin vs.
placebo) were Bonferroni-corrected for multiple compari-
sons. The results are expressed as the mean values with 95%
CIs in the text, and as the mean values 6 SD in the table,
and as the mean values 6 SE in figures.
RESULTS
Mean arterial pressure and heart rate. Baseline mean
arterial pressure did not differ between treatments (Table 1).
Similarly, heart rate did not differ between treatments
(Table 1). Mean arterial pressure and heart rate did not alter
significantly after administration of furosemide with any of
the three treatments or after the administration of NTG.
Forearm blood flow. Baseline forearm blood flow was
similar for all treatments (Table 1). Forearm blood flow was
not changed by the administration of furosemide or NTG
on any study day.
FVC. Baseline FVC did not differ between treatments
(Table 1). In the compound symmetry mixed model, the
effects of period (p 5 0.53) and time (p 5 0.84) and the
interaction of time with period (p 5 0.34) were nonsignif-
icant. In the placebo period, the mean (95% CI) response to
furosemide over 20 min was a 2.2% (20.9% to 5.2%)
increase in FVC. After pretreatment with 300 mg of aspirin,
there was a 3.7% (26.8% to 20.7%) fall in FVC when
furosemide was administered. After 75 mg aspirin, there
was a 1.1% (24.2% to 1.9%) fall in FVC (Fig. 1). The
difference in response to furosemide between placebo,
75 mg aspirin and 300 mg aspirin was statistically significant
(p 5 0.020 by the overall F test, placebo vs. 75 mg aspirin
vs. 300 mg aspirin). The response to furosemide after
pretreatment with placebo was not significantly different
from the response after pretreatment with 75 mg aspirin
(p 5 0.29 after Bonferroni correction, placebo vs. 75 mg
aspirin), and was statistically different for 300 mg aspirin
(p 5 0.017 after Bonferroni correction, placebo vs. 300 mg
aspirin).
Sublingual NTG caused a 2.1% (95% CI 21.6% to 5.8%)
increase in FVC (Fig. 2). This was not statistically different
from the increase observed with furosemide administration
after placebo pretreatment (p 5 0.95, NTG vs. furosemide
and placebo), with little evidence of a trend over time (p 5
0.65) or an interaction between treatment and time (p 5
0.25).
DISCUSSION
Furosemide caused an increase in FVC in our patients with
CHF. Previously, venodilation has only been described in
patients with acute heart failure secondary to myocardial
infarction (4) and in salt-depleted healthy volunteers (5,15–
19). Our data support the hypothesis that furosemide has a
potentially beneficial hemodynamic effect before diuresis
has time to occur, leading to an indirect hemodynamic
change. Furthermore, we have demonstrated that the degree
of venodilation evoked by furosemide is of a similar mag-
nitude to that evoked by the venodilator NTG.
Effect of aspirin and role of prostaglandins in
furosemide-mediated venodilation. A daily dose of 75 mg
and 300 mg of the cyclooxygenase inhibitor aspirin inhib-
ited the venous effect of furosemide in our study. This
observation provides further evidence that prostaglandins
are involved in the mechanism of this vascular action of
furosemide (5,20). What is not clear, however, is precisely
how inhibition of prostaglandin synthesis inhibits venodi-
lation. The most obvious explanation is that aspirin inhibits
the local production of prostaglandins, which provide the
dilatory stimulus to veins. Whether these are released
Figure 1. Mean (6SEM) percent change in venous capacitance in re-
sponse to furosemide according to treatment group. Line with circles 5
placebo group; line with triangles 5 75-mg aspirin group; line with
squares 5 300-mg aspirin group.
Table 1. Baseline Values
Study Day
Placebo Aspirin, 75 mg Aspirin, 300 mg Nitroglycerin
Mean arterial pressure (mm Hg) 75.18 6 16.82 80.18 6 16.82 77.36 6 11.99 79.73 6 12.75
Heart rate (beats/min) 60.82 6 6.55 61.91 6 8.73 63.09 6 5.87 57.64 6 8.76
Forearm blood flow (ml/min per
100 ml forearm volume)
1.23 6 0.30 1.16 6 0.36 1.12 6 0.44 1.34 6 0.38
Venous capacitance (ml/100 ml
forearm volume)
1.47 6 0.34 1.54 6 0.40 1.43 6 0.37 1.61 6 0.32
Data are presented as the mean value 6 SD.
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directly in response to the action of furosemide on the veins
(6), or indirectly in response to the action of angiotensin II
on the venous endothelium, is unknown (17,21). If the
latter is the mechanism, aspirin could block it at two sites.
Aspirin may block furosemide-induced renal renin release,
which is prostaglandin-dependent (20,22,23), and hence,
subsequent generation of angiotensin II. Alternatively, as-
pirin could block the direct effect of angiotensin II on veins,
presumably mediated by cyclooxygenase.
Possible direct effect of aspirin on furosemide action in
veins. A direct effect of furosemide in veins may be more
likely and has previously been described by Pickkers et al.
(6). In their study, furosemide was found to have a direct
dilatory effect on the veins on the dorsum of the hands of
healthy volunteers. The effect was independent of nitric
oxide, and the concentration of furosemide in the veins was
far less than the supratherapeutic concentrations that are
needed to inhibit Na1/K1/2Cl– ion channels (24). Instead,
the authors found that the effect of furosemide was blocked
by cyclooxygenase inhibition (with indomethacin), and was
therefore deemed to be prostaglandin-dependent. However,
this direct action of furosemide has not been reported by all
investigators (25). Differences in the venous constrictor used
and the percentage of preconstriction of the veins before
furosemide was administered, however, could account for
this discrepancy
Further support for the hypothesis that furosemide stim-
ulates prostaglandin release through action on the venous
endothelium comes from a recent in vitro study by Liguori
et al. (26). These authors studied the effects of therapeutic
concentrations of furosemide on cultures of human umbil-
ical vein endothelium. They reported that secretion of
prostacyclin, measured indirectly by 6-ketoPGF51a produc-
tion, increased within 5 min of exposure of the culture to
furosemide. Secretion was maximal at ;15 min and was
maintained for 20 to 30 min. This time scale for the release
of prostacyclin fits well with our finding, as well as that of
others (4,15,16), that the venous dilator effect of furosemide
occurs within 15 to 20 min of drug administration in vivo.
Possible venoconstrictor effect of furosemide in presence
of aspirin. It is possible that aspirin did not just block the
venodilator action of furosemide, it may have even changed
the response to a venoconstrictor one. This might argue for
at least some indirect vascular effects of furosemide. In other
words, it would seem that the most likely explanation for
this reversal of the action of furosemide is that when
angiotensin II-stimulated vasodilator prostanoid production
is inhibited by aspirin, the unopposed vasoconstrictor effect
of angiotensin II is revealed (whereas, normally, it is
completely negated by the prostanoids).
Study limitations. The present study was potentially lim-
ited by the crossover design used (i.e., because of the risk of
a carryover effect). Given the short-lived effect of low dose
aspirin on the blood vessel wall, a carryover effect seems
most unlikely at the time of the vascular studies, which were
carried out at the end of 14 days of randomized treatment.
A small sample size and the measurement of the response in
only one venous system also may limit this study.
It is not known, from these data, whether all venous beds
in the body respond similarly to furosemide. Nevertheless,
we have been able to show that furosemide has an effect of
similar magnitude to that of the recognized generalized
venodilator NTG. Although 9 of 11 patients were taking
aspirin at the time of NTG administration, cyclooxgenase
inhibitors are known to not inhibit nitrate-induced venodi-
lation (27). The degree of venodilation obtained in our
study was also in keeping with that seen previously in older
patients on NTG (28).
Conclusions. We have demonstrated that venodilation
occurs in patients with CHF in the minutes after the
administration of a 20-mg intravenous dose of furosemide.
The degree of venodilation is comparable to that which
occurs after sublingual NTG administration. This is obvi-
ously potentially advantageous, even more so in the clinical
scenario of acute heart failure. Our observation that veno-
dilation could be inhibited by both high and low dose
aspirin further questions the use of aspirin in patients with
CHF (29–31).
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